Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Evaluation of an ab-interno subconjunctival drainage device in the management of glaucoma: nine month results

Poster Details

First Author: S.Sabeti CANADA

Co Author(s):    S. Han   G. Miller   R. Chevrier   D. Marshall   R. Buhrmann        

Abstract Details


The XEN implant is currently the only device that offers an ab-interno approach to subconjunctival drainage in the surgical management of glaucoma. We hope to add to the limited literature on this device by reporting on our experiences in terms of post-operative outcomes and complications associated with its use.


University of Ottawa Eye Institute


This is a retrospective and prospective chart review of 108 eyes that have undergone XEN implantation as standard of care for glaucoma at our institution. Data has been collected on demographic characteristics, as well as pre- and post-operative variables including intraocular pressure (IOP), number of classes of glaucoma medications used, and visual acuities. Primary outcomes include mean reduction in IOP as well as change in median number of classes of glaucoma medications used. Secondary outcomes will include intra- and post-operative complications.


One hundred eight eyes were analyzed. Mean pre-operative IOP was 23.1 mmHg. Mean change from baseline was -7.3 mmHg (95% CI -9.1, -5.5), -6.7 mmHg (95% CI -9.0, -4.4), -7.6 mmHg (95% CI -9.9, -5.2), and -8.4 mmHg (95% CI -12.3, -4.6), at 1, 2, 6, and 9 months, respectively (p<0.05). Based on 34 eyes that completed 9-month follow-up, mean IOP was 13.9 mmHg, and 9 eyes (26.5%) required glaucoma medications. The median number of glaucoma medications needed at baseline was 4.0 (IQR 3.0-4.0) and 0.0 (IQR 0.0-2.0) at 9 months. There were 69 needling events in 41 eyes.


The XEN implant appears to be effective at lowering IOP in the management of glaucoma based on our 9-month data. Data collection at our institution is ongoing and continued monitoring of outcomes and complications will allow further insight into the safety profile of the device.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to Poster listing